Blocking Liver Enzyme Could Increase Cancer Risk, Australian Study Finds
Table of Contents
A new study challenges the prevailing belief that inhibiting a key cellular enzyme protects against liver disease, suggesting it may actually increase the risk of chronic liver damage and cancer as individuals age. Published in the journal Science Advances, the research from the University of Adelaide highlights the complex role of Caspase-2 in maintaining liver health.
Australian researchers warn that targeting this enzyme could have unintended consequences, especially for older populations. The study reveals that the loss of Caspase-2 leads to abnormal liver cell development, triggering a cascade of harmful effects.
caspase-2: A Double-Edged Sword for Liver Health
The research team discovered that Caspase-2 plays a critical role in maintaining the genetic stability of liver cells and regulating fat levels within the organ.Liver cells naturally contain extra copies of genetic material – a condition known as polyploidy – which helps them withstand stress.However, the study demonstrates that without Caspase-2, abnormally high levels of polyploidy become detrimental.
“Liver cells normally have extra copies of genetic material – polyploidy – and although this feature can help the liver cope with stress, our study shows that without the enzyme Caspase-2, abnormally high levels of polyploidy in the liver can be harmful,” a lead researcher explained.
Mouse Model Reveals Increased Cancer Risk
Experiments conducted on mice revealed a stark correlation between Caspase-2 deficiency and liver disease progression. Mice lacking a functional version of the enzyme developed abnormally large liver cells with meaningful genetic and cellular damage. Over time, thes animals exhibited signs of chronic inflammation and hepatitis-like liver disease, including scarring and oxidative damage.
Notably, older mice without Caspase-2 were significantly more prone to developing liver cancer, with an incidence rate up to four times higher than that of normal mice. The research indicates that Caspase-2 is essential for eliminating damaged liver cells that accumulate with age, and its absence allows these cells to proliferate and contribute to tumor formation.
Implications for Drug Development
These findings directly challenge the growing interest in Caspase-2 inhibitors as a potential treatment for hepatic steatosis (fatty liver disease).The study underscores the need for caution when targeting this pathway and suggests that a more nuanced approach is required.
“The findings contradict assumptions that inhibiting Caspase-2 is universally beneficial, showing that this enzyme is essential for removing liver cells damaged with age, without which the cells accumulate and fuel cancer,” a researcher stated.The study’s authors emphasize the importance of considering the long-term effects of Caspase-2 inhibition, particularly in aging populations, as researchers move forward with drug development.
Here’s a breakdown answering the “Why, Who, What, and How” questions, transforming the update into a substantive news report:
Why: Researchers investigated the role of Caspase-2, a cellular enzyme, in liver health, aiming to understand its potential as a therapeutic target for liver disease.They sought to determine if inhibiting Caspase-2 would be beneficial.
Who: The study was conducted by researchers at the University of Adelaide in Australia. The research involved experiments on mice and analysis of cellular processes.
What: The study found that inhibiting Caspase-2,contrary to
